Treatment of MRSA in Patients with Sulfa Allergy

First-Line Treatment Options

The Infectious Diseases Society of America recommends vancomycin as the first-line therapy for most MRSA infections in sulfa-allergic patients, with a dosing regimen of 15-20 mg/kg/dose IV every 8-12 hours 1, 2, 3
Vancomycin dosing should be based on actual body weight, not to exceed 2 g per dose, with target trough concentrations of 15-20 μg/mL for serious infections 2

For skin and soft tissue infections, clindamycin is recommended at 300-450 mg PO three times daily, or linezolid at 600 mg PO twice daily, with a duration of 5-10 days based on clinical response 3, 5, 6
For bacteremia and endocarditis, vancomycin is recommended at 15-20 mg/kg IV every 8-12 hours, with a duration of 2 weeks for uncomplicated bacteremia and 4-6 weeks for complicated bacteremia or endocarditis 2, 4
For pneumonia, vancomycin is recommended at 15-20 mg/kg IV every 8-12 hours, or linezolid at 600 mg IV/PO twice daily, with a duration of 7-21 days 2, 4

For pediatric patients, vancomycin is recommended at 15 mg/kg/dose IV every 6 hours for serious infections, with clindamycin at 10-13 mg/kg/dose IV every 6-8 hours, and linezolid at 10 mg/kg/dose PO/IV every 8 hours 1, 6, 7

Monitoring of vancomycin trough levels is recommended before the fourth dose, with maintenance of trough levels at 15-20 μg/mL for serious infections, and regular monitoring of renal function 2
In cases of treatment failure, source control, switching to an alternative agent, or combination therapy may be considered, with high-dose daptomycin (10 mg/kg/day) in combination with another agent for persistent MRSA bacteremia 2